Failures at Novartis have prompted U.K. | Failures at Novartis have prompted the U.K. marketing watchdog to warn that “companies should be on high alert” when working with third parties to ...

Novartis argues that it needs the court to issue its decision on the ‘918 patent case quickly because MSN has indicated it’s willing to launch at risk as soon as it has approval and isn’t ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu ...

Novartis Pharma AG. Ad hoc announcement pursuant to Art. 53 LR. At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit ...

While the execs with Lilly and Novartis appeared curious but cautious about PD-(L)1xVEGF bispecifics, it’s worth noting that biopharma companies often present a degree of impartiality on hot ...

Novartis in Focus. Based in Basel, Novartis (NVS) is in the Medical sector, and so far this year, shares have seen a price change of 21.05%. Currently paying a dividend of $2.6 per share, the ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

See the latest Novartis AG ADR stock price (NVS:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Novartis closes on filings for oral BTK drug remibrutinib as a treatment for chronic spontaneous urticaria after reporting 52-week data.

Novartis started a review of the business in October 2021, after Sandoz had been suffering from pressure on sales and operating profits for several years due mainly to pricing pressures, ...